Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The contribution of founder mutations to early-onset breast cancer in French-Canadian women.

Clinical genetics - 1 Nov 2009

Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Giroux S, Narod S A, Rousseau F, Foulkes W D

Abstract excerpt

In an ethnically-homogeneous population, it is valuable to identify founder mutations in cancer-predisposing genes. Founder mutations have been found in four breast-cancer-predisposing genes in French-Canadian breast cancer families. The frequencies of the mutant alleles have been measured neithe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Checkpoint Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fanconi Anemia Complementation Group N Protein

Share to Founder Effect

Share to France

Share to Quebec

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 19863560
DOI: 10.1111/j.1399-0004.2009.01277.x

Genes

BRCA2
CHEK2
BRCA1
PALB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19863560-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The contribution of founder mutations to early-onset breast cancer in French-Canadian women.PMID 19863560Read ↗

[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].Semantic proximity Read ↗

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls.Semantic proximity Read ↗

Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.Semantic proximity Read ↗

Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal.Semantic proximity Read ↗

Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women.Semantic proximity Read ↗

Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.Semantic proximity Read ↗

Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.Semantic proximity Read ↗

Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.Semantic proximity Read ↗

The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.Semantic proximity Read ↗

Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.Semantic proximity Read ↗

Germline TP53 mutational spectrum in French Canadians with breast cancer.Semantic proximity Read ↗

Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.